Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure

[1]  M. Hiraoka,et al.  Comparison of three radiotherapy treatment planning protocols of definitive external-beam radiation for localized prostate cancer , 2005, International Journal of Clinical Oncology.

[2]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[3]  H. Sandler,et al.  RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? , 2003, International journal of radiation oncology, biology, physics.

[4]  A. Zietman,et al.  Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. , 2003, International journal of radiation oncology, biology, physics.

[5]  T. Habuchi,et al.  Total Cystoprostatectomy in the Treatment of Locally Advanced Prostate Carcinoma , 2003, Aktuelle Urologie.

[6]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Rubin,et al.  Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. , 2002, International journal of radiation oncology, biology, physics.

[8]  M. Keyes,et al.  Impact of neoadjuvant androgen ablation and other factors on late toxicity following external beam prostate radiation , 2002 .

[9]  C. Reddy,et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[11]  G. Sanguineti,et al.  Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma , 2002, British Journal of Cancer.

[12]  J. Adolfsson,et al.  Treatment of Patients with Clinical T3 Prostate Cancer , 2002, Scandinavian journal of urology and nephrology.

[13]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[14]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[15]  D. Grignon,et al.  Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Grignon,et al.  Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. , 2000, International journal of radiation oncology, biology, physics.

[17]  Y. Ohashi,et al.  Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. , 1999, Urology.

[18]  N. Oyama,et al.  Long-term treatment results of elderly patients with prostate cancer in Japan: an analysis of prognostic factors. , 1999, Japanese journal of clinical oncology.

[19]  W. Hop,et al.  Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. , 1998, The Journal of urology.

[20]  P. Walsh.  RE: EDITORIAL COMMENT: TAKING ON PROSTATE CANCER , 1997 .

[21]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[22]  H. Levin,et al.  Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery? , 1997, International journal of radiation oncology, biology, physics.

[23]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[24]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[25]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[27]  P. Walsh,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997 .

[28]  D. Ai,et al.  Development of an integrated radiotherapy network system. , 1996, International journal of radiation oncology, biology, physics.

[29]  O. Nordle,et al.  Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group. , 1995, The Journal of urology.

[30]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[31]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[32]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[33]  M. Keyes,et al.  Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[34]  G E Hanks,et al.  Is there an increased risk of second primaries following prostate irradiation? , 1998, International journal of radiation oncology, biology, physics.

[35]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[36]  P. Schellhammer,et al.  Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. , 1997, European urology.

[37]  J. Forman,et al.  Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. , 1995, Cancer investigation.

[38]  Pharmacia Ab.  IMMEDIATE ESTROGEN OR ESTRAMUSTINE PHOSPHATE THERAPY VERSUS DEFERRED ENDOCRINE TREATMENT IN NONMETASTATIC PROSTATE CANCER: A RANDOMIZED MULTICENTER STUDY WITH 15 YEARS OF FOLLOWUP ROLF LUNDGREN, OMAN NORDLE, KENNETH JOSEFSSON AND THE SOUTH SWEDEN PROSTATE CANCER STUDY GROUP* , 1995 .